CCND1 and triple-negative breast carcinoma: It has been reported previously that the cyclin D1-CDK4 and cyclin D3-CDK6 pairs can regulate glucose metabolism [10,12] and that palbociclib administration reduces glucose metabolism in triple negative breast cancer in vitro models [34].